A New Approach to Clinical Trial Planning: How Mid-Market and Emerging Pharma Can Take Greater Control of Patient Enrollment

An executive summary describes connected enrollment planning for emerging and mid-size pharmaceutical companies, linking site choices, schedule forecasts and adjustments during studies. It uses illustrative trial and portfolio examples to describe how ZAIDYN supports these decisions with shared data.

Why it matters: The summary addresses enrollment planning across site selection, forecasting and study adjustments for emerging and mid-size pharmaceutical companies.